Ortex estimates 99% of MiniMed float sold short as short interest surges
Data provider Ortex estimated that 99% of MiniMed Group Inc.'s float was sold short, up sharply from prior levels.
Why it matters
The extreme short interest creates a potential short squeeze risk and reflects unusual market dynamics around the Medtronic spin-off and share exchange offer.
Key facts
Ortex estimated 99% of MiniMed Group Inc.'s float was sold short
99 %Reported by Protos
Short interest rose from 47.6% on September 15 and 77% a week earlier
47.6 %Reported by Protos
Available stock to borrow at 0.08% of short interest
0.08 %Reported by Protos
MiniMed was spun off from Medtronic in a March 2026 IPO
Reported by Protos
Medtronic owned 90% of MiniMed as of September 14
90 %Reported by Protos
Medtronic offered a tax-free exchange of MiniMed shares for Medtronic shares
Reported by Protos
What happened
Protos reported that Ortex estimated 99% of MiniMed Group Inc.'s float was sold short, a near-total shorting of available shares. Short interest had risen from 47.6% on September 15 and 77% a week earlier, with available stock to borrow at just 0.08% of short interest. MiniMed was spun off from Medtronic in a March 2026 IPO; Medtronic still owned 90% of MiniMed as of September 14 and was offering a tax-free exchange of MiniMed shares for Medtronic shares. The anomaly stems from this swap arrangement with a Friday deadline.
How the story developed
Affected entities
Original sources
| Publisher | Report | Role | Published |
|---|---|---|---|
| Protos Crypto media | How MiniMed ended up with 99% of its float sold short | Original |